Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Double-Blind, Randomized, Placebo-Controlled Trial in Healthy Volunteers to Examine Safety, Tolerability, Plasmapharmacokinetics of TMC589337andTMC589354 After Increasing Single Oral Doses and in an Open-Label Part After Different Repeated Doses in Combination With Single Oral Dose of TMC310911.

Next Previous
Trial Profile

Phase I, Double-Blind, Randomized, Placebo-Controlled Trial in Healthy Volunteers to Examine Safety, Tolerability, Plasmapharmacokinetics of TMC589337andTMC589354 After Increasing Single Oral Doses and in an Open-Label Part After Different Repeated Doses in Combination With Single Oral Dose of TMC310911.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TMC 310911 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

  • 27 Oct 2016 Status changed from discontinued to withdrawn prior to enrolment.
  • 21 Jul 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 01 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top